Relmada Therapeutics (RLMD) Revenue (2012 - 2013)
Relmada Therapeutics' (RLMD) quarterly Revenue came in at $1850.0 in Q4 2013, down 13.91% year-on-year from $2149.0 in Q4 2012, and up 191.8% on a QoQ basis from $634.0 in Q2 2013.
Relmada Therapeutics (RLMD) Revenue (2012 - 2013) Analysis & Trends
Relmada Therapeutics (RLMD) has 2 years of Revenue data on file, last reported at $1850.0 in Q4 2013.
- On a quarterly basis, Revenue fell 13.91% year-over-year to $1850.0 in Q4 2013; TTM through Nov 2013 was $4830.0, a N/A change from a year earlier, with the FY2013 full-year figure at $5129.0, down 35.41% from the prior year.
- Revenue for Q4 2013 stood at $1850.0, up from $634.0 in the prior quarter.
- Over the last five years, Revenue for RLMD reached as high as $2346.0 in Q1 2013 and fell as low as $400.0 in Q2 2012.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 1.51 Bn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 2.99 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 3.61 Bn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | 1.30 Bn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | - |
| 10 | Relmada Therapeutics | 451.17 Mn | 451.17 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Nov 30, 2013 | 1,850.00 |
| May 31, 2013 | 634.00 |
| Feb 28, 2013 | 2,346.00 |
| Nov 30, 2012 | 2,149.00 |
| Aug 31, 2012 | 1,515.00 |
| May 31, 2012 | 400.00 |